RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Anika Therapeutics Stock

Anika Therapeutics EBIT 2024

Anika Therapeutics EBIT

-1.75 M USD

Ticker

ANIK

ISIN

US0352551081

WKN

889120

In 2024, Anika Therapeutics's EBIT was -1.75 M USD, a -90.87% increase from the -19.17 M USD EBIT recorded in the previous year.

The Anika Therapeutics EBIT history

YEAREBIT (undefined USD)
2028e19.58
2027e14.28
2026e7.01
2025e2.77
2024e-1.75
2023-19.17
2022-19.4
20212.6
202014.2
201934.2
201821.7
201745.7
201650.6
201548.1
201461.4
201332.3
201222.2
201114
20107.5
20097.8
20084.2
20076.6
20065.4
20058.6
20046.4

Anika Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Anika Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Anika Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Anika Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Anika Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Anika Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Anika Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Anika Therapeutics’s growth potential.

Anika Therapeutics Revenue, EBIT and net profit per share

DateAnika Therapeutics RevenueAnika Therapeutics EBITAnika Therapeutics Net Income
2028e240.01 M undefined19.58 M undefined21.37 M undefined
2027e219.91 M undefined14.28 M undefined15.99 M undefined
2026e126.72 M undefined7.01 M undefined5.23 M undefined
2025e116.79 M undefined2.77 M undefined-2.99 M undefined
2024e153.2 M undefined-1.75 M undefined-39.3 M undefined
2023166.66 M undefined-19.17 M undefined-82.67 M undefined
2022156.2 M undefined-19.4 M undefined-14.9 M undefined
2021147.8 M undefined2.6 M undefined4.1 M undefined
2020130.5 M undefined14.2 M undefined-24 M undefined
2019114.6 M undefined34.2 M undefined27.2 M undefined
2018105.6 M undefined21.7 M undefined18.7 M undefined
2017113.4 M undefined45.7 M undefined31.8 M undefined
2016103.4 M undefined50.6 M undefined32.5 M undefined
201593 M undefined48.1 M undefined30.8 M undefined
2014105.6 M undefined61.4 M undefined38.3 M undefined
201375.1 M undefined32.3 M undefined20.6 M undefined
201271.4 M undefined22.2 M undefined11.8 M undefined
201164.8 M undefined14 M undefined8.5 M undefined
201055.6 M undefined7.5 M undefined4.3 M undefined
200940.1 M undefined7.8 M undefined3.7 M undefined
200835.8 M undefined4.2 M undefined3.6 M undefined
200730.8 M undefined6.6 M undefined6 M undefined
200626.8 M undefined5.4 M undefined4.6 M undefined
200529.8 M undefined8.6 M undefined5.9 M undefined
200426.5 M undefined6.4 M undefined11.2 M undefined

Anika Therapeutics stock margins

The Anika Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Anika Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Anika Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Anika Therapeutics's sales revenue. A higher gross margin percentage indicates that the Anika Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Anika Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Anika Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Anika Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Anika Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Anika Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Anika Therapeutics Margin History

Anika Therapeutics Gross marginAnika Therapeutics Profit marginAnika Therapeutics EBIT marginAnika Therapeutics Profit margin
2028e61.85 %8.16 %8.9 %
2027e61.85 %6.49 %7.27 %
2026e61.85 %5.53 %4.13 %
2025e61.85 %2.37 %-2.56 %
2024e61.85 %-1.14 %-25.65 %
202361.85 %-11.5 %-49.6 %
202259.92 %-12.42 %-9.54 %
202156.09 %1.76 %2.77 %
202052.87 %10.88 %-18.39 %
201974.96 %29.84 %23.73 %
201870.36 %20.55 %17.71 %
201775.93 %40.3 %28.04 %
201676.79 %48.94 %31.43 %
201577.31 %51.72 %33.12 %
201480.21 %58.14 %36.27 %
201369.64 %43.01 %27.43 %
201259.38 %31.09 %16.53 %
201158.64 %21.6 %13.12 %
201057.01 %13.49 %7.73 %
200966.08 %19.45 %9.23 %
200863.13 %11.73 %10.06 %
200761.36 %21.43 %19.48 %
200658.58 %20.15 %17.16 %
200562.75 %28.86 %19.8 %
200462.26 %24.15 %42.26 %

Anika Therapeutics Aktienanalyse

What does Anika Therapeutics do?

Anika Therapeutics Inc is a global biotechnology company specializing in the development and manufacturing of therapeutic products for orthopedic, ophthalmologic, and dermatologic treatment. It was founded in 1992 in Bedford, Massachusetts and has since maintained its headquarters there while expanding its operations worldwide. Business model Anika Therapeutics' business model is based on the development, manufacturing, and commercialization of innovative and cost-effective medical devices that use natural substances to enable rapid and powerful repair of the human body in various orthopedic, ophthalmologic, and dermatologic conditions. The company leverages its expertise in hyaluronan biology and technology to produce products based on this substance for the regeneration and healing of tissues such as cartilage, skin, and eyes. History Anika Therapeutics was founded by Charles Sherwood and Jeffrey Palmer to develop a synthetic hyaluronic acid product for the treatment of joint disorders. The first clinical study was conducted in 1996, and Anika received FDA approval for the product, marketed as Orthovisc, in 1999. Since then, Anika has expanded its presence in the industry through acquisitions, partnerships, and expansion into new geographical areas. Divisions Orthopedics In orthopedics, Anika Therapeutics offers a wide range of products for the treatment of joint disorders such as osteoarthritis and arthritis. These include Orthovisc, the company's original product, as well as Monovisc, a single-component viscosupplement that allows for easy injection into the joint, thus reducing the procedure and recovery time. Another product is Cingal, a combination product of hyaluronic acid and corticosteroid that provides effective pain relief. Ophthalmology Anika Therapeutics also manufactures products for ophthalmology. The company has a portfolio of products used for surgical procedures such as cataract surgery and vitrectomy (a surgery on the eye's vitreous body). These are available under the brand names Visian and Amvisc. Dermatology Anika Therapeutics is also active in dermatology, where it offers products for skin regeneration. This portfolio includes solutions such as Hyalofill, a hyaluronic acid-based filler substance used for restoring skin elasticity and treating wrinkles and scars. In summary, Anika Therapeutics is a global biotechnology company specializing in the development, manufacturing, and commercialization of therapeutic products in the field of orthopedics, ophthalmology, and dermatology. The company leverages its expertise in hyaluronan biology and technology to develop innovative and cost-effective medical devices that enable rapid and powerful repair of the human body in various conditions. Since its founding in 1992, the company has built a successful history of growth and expansion through acquisitions, partnerships, and expansion into new geographical areas. Anika Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Anika Therapeutics's EBIT

Anika Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Anika Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Anika Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Anika Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Anika Therapeutics stock

How much did Anika Therapeutics achieve in EBIT for the current year?

In the current year, Anika Therapeutics has achieved an EBIT of -1.75 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Anika Therapeutics.

How has the EBIT of Anika Therapeutics developed in recent years?

The EBIT of Anika Therapeutics has increased by -90.873% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Anika Therapeutics?

The EBIT of Anika Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Anika Therapeutics pay?

Over the past 12 months, Anika Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anika Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Anika Therapeutics?

The current dividend yield of Anika Therapeutics is .

When does Anika Therapeutics pay dividends?

Anika Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anika Therapeutics?

Anika Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Anika Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anika Therapeutics located?

Anika Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anika Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anika Therapeutics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Anika Therapeutics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Anika Therapeutics in the year 2023?

In the year 2023, Anika Therapeutics distributed 0 USD as dividends.

In which currency does Anika Therapeutics pay out the dividend?

The dividends of Anika Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Anika Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Anika Therapeutics

Our stock analysis for Anika Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Anika Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.